Rapid Dose Therapeutics Corp. (CSE:DOSE)
Canada · Delayed Price · Currency is CAD 0.0900
0.00 (0.00%)
Aug 7, 2026, 5:22 PM EST
Rapid Dose Therapeutics Income Statement
Financials in millions CAD. Fiscal year is March - February.
Millions CAD. Fiscal year is Mar - Feb.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
| 2.58 | 2.77 | 2.09 | 1.02 | 0.72 | 1.75 | |
Revenue Growth | 4.30% | 33.00% | 104.34% | 42.06% | -59.00% | 131.98% |
Cost of Revenue | 1.29 | 1.41 | 0.91 | 0.46 | 0.36 | 0.41 |
Gross Profit | 1.28 | 1.36 | 1.18 | 0.56 | 0.36 | 1.34 |
Selling, General & Admin | 2.45 | 2.67 | 3.55 | 2.45 | 2.46 | 2.99 |
Research & Development | 0.05 | 0.03 | 0.15 | 0.43 | 0.09 | 0.36 |
Operating Expenses | 3.18 | 3.53 | 5.35 | 3.65 | 3.9 | 5.65 |
Operating Income | -1.89 | -2.17 | -4.17 | -3.09 | -3.54 | -4.3 |
Interest Expense | -1.27 | -1.22 | -1.23 | -0.66 | -0.26 | -0.13 |
Interest & Investment Income | - | - | - | - | - | 0 |
Currency Exchange Gain (Loss) | - | - | - | - | -0 | 0.02 |
Other Non Operating Income (Expenses) | - | - | - | - | - | 0.01 |
EBT Excluding Unusual Items | -3.17 | -3.39 | -5.4 | -3.75 | -3.81 | -4.4 |
Impairment of Goodwill | - | - | - | - | - | -4.08 |
Other Unusual Items | - | - | - | -0.56 | - | - |
Pretax Income | -3.17 | -3.39 | -5.4 | -4.31 | -3.81 | -8.49 |
Net Income | -3.17 | -3.39 | -5.4 | -4.31 | -3.81 | -8.49 |
Net Income to Common | -3.17 | -3.39 | -5.4 | -4.31 | -3.81 | -8.49 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 134 | 133 | 125 | 105 | 103 | 100 |
Shares Outstanding (Diluted) | 134 | 133 | 125 | 105 | 103 | 100 |
Shares Change | 5.68% | 6.73% | 18.68% | 1.50% | 3.19% | 28.83% |
EPS (Basic) | -0.02 | -0.03 | -0.04 | -0.04 | -0.04 | -0.08 |
EPS (Diluted) | -0.02 | -0.03 | -0.04 | -0.04 | -0.04 | -0.08 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
Free Cash Flow | 0.21 | -0.27 | -1.15 | -2.29 | -0.86 | -3.04 |
Free Cash Flow Per Share | 0.00 | -0.00 | -0.01 | -0.02 | -0.01 | -0.03 |
Gross Margin | 49.83% | 49.15% | 56.59% | 55.21% | 49.67% | 76.76% |
Operating Margin | -73.58% | -78.29% | -200.07% | -302.45% | -493.36% | -245.55% |
Profit Margin | -123.09% | -122.23% | -259.18% | -422.03% | -530.42% | -484.47% |
Free Cash Flow Margin | 8.18% | -9.78% | -55.27% | -224.91% | -120.27% | -173.52% |
EBITDA | -1.82 | -2 | -3.95 | -2.75 | -3.2 | -3.82 |
EBITDA Margin | -70.78% | -72.11% | -189.66% | -269.93% | - | -218.31% |
D&A For EBITDA | 0.07 | 0.17 | 0.22 | 0.33 | 0.34 | 0.48 |
EBIT | -1.89 | -2.17 | -4.17 | -3.09 | -3.54 | -4.3 |
EBIT Margin | -73.58% | -78.29% | -200.07% | - | - | -245.55% |